24 November 2010 in Artificial Organs
14 September 2021 in Heart and Vessels
19 November 2024 in Journal of the American Heart Association
TGthe TICAP/PERSEUS Study Group
the TICAP/PERSEUS Study Group
+9
Background: Cardiosphere‐derived cell (CDC) infusion was associated with better clinical outcomes at 2 years in patients with single ventricle heart disease. The current study investigates time‐to‐event outcomes at 8 years. Methods and Results: This cohort enrolled patients with single ventricles who underwent stage 2 or stage 3 palliation from January 2011 to January 2015 at 8 centers in Japan. The primary outcomes were time‐dependent CDC treatment effects on death and late complications during 8 years of follow‐up, assessed by restricted mean survival time. Among 93 patients enrolled (mean age, 2.3±1.3 years; 56% men), 40 received CDC infusion. Overall survival for CDC‐treated versus control patients did not differ at 8 years (hazard ratio [HR], 0.60 [95% CI, 0.21–1.77]; P =0.35). Treatment effect had nonproportional hazards for death favoring CDCs at 4 years (restricted mean survival time difference +0.33 years [95% CI, 0.01–0.66]; P =0.043). In patients with heart failure with reduced ejection fraction, CDC treatment effect on survival was greater over 8 years (restricted mean survival time difference +1.58 years [95% CI, 0.05–3.12]; P =0.043). Compared with control participants, CDC‐treated patients showed lower incidences of late failure (HR, 0.45 [95% CI, 0.21–0.93]; P =0.027) and adverse events (subdistribution HR, 0.50 [95% CI, 0.27–0.94]; P =0.036) at 8 years. Conclusions: By 8 years, CDC infusion was associated with lower hazards of late failure and adverse events in single ventricle heart disease. CDC treatment effect on survival was notable by 4 years and showed a durable clinical benefit in patients with heart failure with reduced ejection fraction over 8 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01273857 and NCT01829750.
16 December 2025 in Journal of the American Heart Association
Background: Management strategies of unplanned hospitalizations (UPH) vary and have not been well characterized in patients with Fontan circulation. Methods: We prospectively followed 3226 Fontan patients for 3 years to characterize the current UPH status and elucidate the associations between in‐hospital management strategies and postdischarge outcomes. Results: A total of 243 UPHs occurred (2.5 cases/100 person‐years). Fontan‐related UPHs accounted for 154 cases (63%), most commonly due to heart failure (19%), protein‐losing enteropathy (16%), hemorrhage (14%), arrhythmia (9%), thromboembolism (3%), and plastic bronchitis (2%). Fontan‐unrelated UPHs (89 cases; 37%) were mainly due to infections (19%). Adult patients were more frequently hospitalized for hemorrhage and thromboembolism ( P <0.05). The longest length of hospital stay was observed in protein‐losing enteropathy, followed by thromboembolism and heart failure. Among nonpharmacological treatments, oxygen therapy was commonly used, followed by surgical procedures and catheter‐based interventions. Among pharmacological treatments, diuretics were commonly administered, followed by heparin and catecholamines. Of 240 patients discharged alive, 76 (15.4 cases/100 person‐years) were readmitted. Protein‐losing enteropathy was the most frequent cause of readmission, followed by heart failure and hemorrhage. In addition to conventional risk factors, in‐hospital management practices, such as oxygen therapy, surgical intervention, and diuretic adjustment were associated with readmission risk ( P <0.01–0.001). Conclusions: We clarified real‐world practices related to UPHs in Fontan patients. Specific in‐hospital treatment strategies were associated with the risk of readmission. Further studies are warranted to determine the causal relationships between treatment approaches and outcomes for standardized management strategies.
7 April 2022 in Operative Techniques in Thoracic and Cardiovascular Surgery